Rhumbline Advisers Chemo Centryx, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	BUY	$22.17 - $51.8 $256,750 - $599,895	11,581 Added 14.04%	94,082 $4.86 Million
Q2 2022 Aug 11, 2022	BUY	$15.36 - $27.51 $137,472 - $246,214	8,950 Added 12.17%	82,501 $2.04 Million
Q1 2022 May 12, 2022	SELL	$22.22 - $39.12 $173,738 - $305,879	-7,819 Reduced 9.61%	73,551 $1.84 Million
Q4 2021 Feb 10, 2022	SELL	$18.38 - $40.5 $20,603 - $45,400	-1,121 Reduced 1.36%	81,370 $2.96 Million
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $26,781 - $40,294	2,032 Added 2.53%	82,491 $1.41 Million
Q2 2021 Aug 05, 2021	BUY	$9.59 - $50.88 $201,888 - $1.07 Million	21,052 Added 35.44%	80,459 $1.08 Million
Q1 2021 May 06, 2021	SELL	$49.53 - $68.4 $358,151 - $494,600	-7,231 Reduced 10.85%	59,407 $3.04 Million
Q4 2020 Feb 10, 2021	BUY	$47.25 - $65.16 $237,431 - $327,429	5,025 Added 8.16%	66,638 $4.13 Million
Q3 2020 Nov 12, 2020	SELL	$46.35 - $61.69 $524,218 - $697,713	-11,310 Reduced 15.51%	61,613 $3.38 Million
Q2 2020 Aug 13, 2020	BUY	$38.58 - $65.07 $462,612 - $780,254	11,991 Added 19.68%	72,923 $4.2 Million
Q1 2020 May 06, 2020	BUY	$32.73 - $50.78 $214,643 - $333,015	6,558 Added 12.06%	60,932 $2.45 Million
Q4 2019 Feb 05, 2020	BUY	$6.81 - $39.55 $52,866 - $307,026	7,763 Added 16.65%	54,374 $2.15 Million
Q3 2019 Oct 23, 2019	BUY	$6.47 - $8.96 $1,358 - $1,881	210 Added 0.45%	46,611 $316,000
Q2 2019 Aug 14, 2019	BUY	$8.31 - $14.85 $138,752 - $247,950	16,697 Added 56.21%	46,401 $432,000
Q1 2019 May 01, 2019	SELL	$10.01 - $13.89 $8,928 - $12,389	-892 Reduced 2.92%	29,704 $413,000
Q4 2018 Jan 31, 2019	BUY	$9.15 - $12.26 $86,732 - $116,212	9,479 Added 44.89%	30,596 $334,000
Q3 2018 Nov 07, 2018	SELL	$10.49 - $13.72 $13,112 - $17,150	-1,250 Reduced 5.59%	21,117 $267,000
Q2 2018 Aug 06, 2018	SELL	$10.62 - $13.98 $12,860 - $16,929	-1,211 Reduced 5.14%	22,367 $295,000
Q1 2018 May 02, 2018	SELL	$5.9 - $14.99 $2,389 - $6,070	-405 Reduced 1.69%	23,578 $321,000
Q4 2017 Feb 09, 2018	SELL	$5.53 - $8.42 $33,014 - $50,267	-5,970 Reduced 19.93%	23,983 $143,000
Q3 2017 Nov 06, 2017	BUY	$6.5 - $10.69 $194,694 - $320,197	29,953	29,953 $222,000

Others Institutions Holding CCXI

# of Institutions

Shares Held

66.3K

Call Options Held

Put Options Held

View Full List

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account